Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study-Reference-Cited by-同舟云学术

Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study

Published:2015-08-03 Issue:1 Volume:5 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Vincenzi Bruno,Stumbo Luciano,Maltese Giuseppina,Cerbone Linda,Spalato Ceruso Mariella,Badalamenti Giuseppe,Santini Daniele,Tonini Giuseppe,Frezza Anna Maria,De Lisi Delia,Silletta Marianna

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep12077.pdf

Reference18 articles.

1. Italiano, A. et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer 117, 1049–1054 (2011).

2. Casali, P. G. & Blay, J. Y. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 v198–203 (2010).

3. Demetri, G. D. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J. Clin. Oncol. 27, 4188–4196 (2009).

4. Garcia-Carbonero, R. et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22, 1480–1490 (2004).

5. Le Cesne, A. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23, 576–584 (2005).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trabectedin use in soft‐tissue sarcoma patients in a real‐world setting: Data from an Italian national drug‐access registry;International Journal of Cancer;2022-10-13

2. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial;Investigational New Drugs;2017-11-27